• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

快速检索引用检索图表检索高级检索

• 投稿 • 上一篇    下一篇

国内厄贝沙坦与依那普利治疗原发性高血压疗效与安全性的Meta分析

赵琼丹,罗强,吴静   

  1. 郑州大学第一附属医院,郑州大学第一附属医院,郑州大学第一附属医院
  • 收稿日期:2017-04-17 修回日期:2017-07-01 出版日期:2017-08-25
  • 基金资助:
    国家自然科学基金项目(编号:52110765)

Meta-analysis of the Clinical Therapeutic Effects and Safety of Irbesartan vs. Enalapril in the Treatment with Mild to Moderate Hypertension

Zhao qiongdan,Luo qiang and Wu jing   

  1. The First Affiliated Hospital of Zhengzhou University,The First Affiliated Hospital of Zhengzhou University,The First Affiliated Hospital of Zhengzhou University
  • Received:2017-04-17 Revised:2017-07-01 Online:2017-08-25

摘要: 目的:比较厄贝沙坦和依那普利治疗原发性轻、中度高血压的疗效和安全性。方法:采用 Meta 分析对厄贝沙坦和依那普利治疗原发性轻、中度高血压的疗效,安全性进行系统评价,15个随机对照研究共1892例患者纳入实验,其中厄贝沙坦组946例,依那普利组946例,采用RevMan5.3统计软件对同质性结果进行合并分析。结果:同质性检验 : 显效率、总有效率及不良反应, I2=0%,P>0.5;无效率,I2=76%,P<0.00001。合并效应量的估计: 显效率,OR合并=1.59,OR合并 95% 可信区间为1.32~1.93,P<0.00001;总有效率,OR合并=2.10,OR合并 95% 可信区间为1.58~2.78,P<0.000 01;无效率OR合并=0.45,OR合并 95% 可信区间为0.24~0.83,P<0.000 01;不良反应,OR合并=0.29,OR合并 95% 可信区间为0.20~0.42,P<0.000 01。结论:厄贝沙坦治疗轻、中度原发性高血压的显效率、总有效率及安全性均高于依那普利。

Abstract: Objective:To compare the clinical therapeutic effects and safety of irbesartan vs. Enalapril in the treatment with mild to moderate hypertension.Methods:The clinical therapeutic effects and safety of irbesartan vs. Enalapril in the treatment with mild to moderate hypertension were analyzed by meta-analysis .All 1892 cases of patients with mild to moderate hypertension in 15 RCTs were treated with irbesartan(946) or enalapril (946).The homogeneity test and combined test were carried out by RevMan5.3.Results: Homogeneity test showed significant efficiency,total effective rate and adverse drug reaction with I2=0%,P>0.5;inefficiency with I2=76%、P<0.00001.In combined test,significant efficiency,the combined OR=1.59(95% confidence interval ranged from 1.32 to 1.93, P<0.000 01); total effective rate OR=2.10 (95% confidence interval 1.58~2.78, P<0.000 01); inefficiency, OR=0.45 (95% confidence interval 0.24~0.83,P<0.00001);adverse drug reaction OR=0.29 (95% confidence interval 0.20~0.42,P<0.00001).Conclusion: Compared with enalapril, the Clinical efficacy and safety of irbesartan is significantly better in treatment of mild to moderate hypertension, while the incidence of ADR and inefficiency induced by enalapril is more than which induced by irbesartan.